Cargando…
HIV mRNA Vaccines—Progress and Future Paths
The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host’s cells to manufacture protein immunogens which, in turn, are targets for antibo...
Autores principales: | Mu, Zekun, Haynes, Barton F., Cain, Derek W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915550/ https://www.ncbi.nlm.nih.gov/pubmed/33562203 http://dx.doi.org/10.3390/vaccines9020134 |
Ejemplares similares
-
Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles
por: Mu, Zekun, et al.
Publicado: (2021) -
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
por: Pardi, Norbert, et al.
Publicado: (2019) -
mRNA vaccination in breast cancer: current progress and future direction
por: Jiang, Xiao-ting, et al.
Publicado: (2023) -
mRNA vaccines: Past, present, future
por: Karam, Mia, et al.
Publicado: (2022) -
Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development
por: Bonsignori, Mattia, et al.
Publicado: (2017)